PrimeVigilance is committed to minimising the impact of UK’s Withdrawal from the EU
pharmafile | June 14, 2017 | News story | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing |Â Â EU, brexit, primevigilanceÂ
Guildford, UK 14th June, 2017
During May 2017, the EC, EMA and CMDh published communications and questions and answers notifying Marketing Authorisation Holders (of centrally authorised medicine and nationally authorised medicines respectively) of their obligations in relation to Brexit. The communications state that from 30th March 2019 the UK will be considered as a third country (i.e. outside of the EU). According to the EC/EMA communications, centralised marketing authorisations held by UK entities would need to be transferred to an entity within another EU member state prior to the UK exit from the EU. Pharmacovigilance obligations must also continue to take place in an EU member state.
How does this impact our clients?
PrimeVigilance is committed to minimising any impact of Brexit on our clients. As the outcome of the Brexit negations are currently unclear and will continue over a two year period, we will be keeping a close eye on developments and will ensure timely action to ensure continued quality and compliance. Over the coming years, responsibilities of PrimeVigilance EEA QPPVs based in the UK will be smoothly transitioned to our EEA QPPV colleagues based in our EU offices (Frankfurt, Prague and Zagreb). We also offer assistance with selection of the new PSMF location, and the related choice of a new supervisory authority for EEA pharmacovigilance inspections.
Links to EMA and CMDh Brexit communication websites:
CMDh: http://www.hma.eu/535.html
About PrimeVigilance Ltd.
PrimeVigilance is focused on providing high quality pharmacovigilance, medical information and regulatory affairs services. We support pharmaceutical, biotechnology and generics companies in managing the global safety of their products from early clinical trial development through full post marketing activities. We have proven expertise and the international presence to assure clients that patients and products will be adequately protected. We have over 350 experienced professionals across all our offices in Europe, UK and the USA.
Please send us queries at info@primevivigilance.com and for information about all our other services please visit our website at http://www.primevigilance.com/
Related Content
Sharp invests $100m in US and EU manufacturing and packaging facilities
Sharp Services, a pharmaceutical packaging and sterile manufacturing specialist, has announced investments totalling $100m across …
Sarclisa recommended for EU approval in newly diagnosed multiple myeloma
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended Sanofi’s …
EU approval granted for rare kidney disease treatment
The EU has granted marketing authorisation (MA) for Filspari – CSL Vifor and Travere Therapeutics’ …
